{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-022876","form_type":"8-K","ticker":"VXRT","cik":"0000072444","company_name":"Vaxart, Inc.","filed_at":"2026-07-07T12:00:09+00:00","discovered_at":"2026-07-07T12:05:02.488022+00:00","generated_at":"2026-07-07T12:05:15.548163+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vaxart reports positive 12-month safety data from Phase 2b sentinel cohort of oral COVID-19 vaccine","bullets":["No vaccine-related SAEs or sustained Grade 3+ AEs in either arm (201 oral pill, 199 mRNA).","Most common AEs for oral pill: malaise/fatigue (20.9%), headache (18.9%), anorexia (10.0%).","Sentinel cohort not powered for efficacy; 33 symptomatic COVID cases in oral arm vs 30 in mRNA arm.","Complete study data (~5,000 main cohort participants) anticipated in 2027.","Project NextGen/BARDA award valued at up to $344.8 million supports the trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-022876","json":"https://secwatch.observer/filing/0001437749-26-022876.json","markdown":"https://secwatch.observer/filing/0001437749-26-022876.md","text":"https://secwatch.observer/filing/0001437749-26-022876.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/72444/000143774926022876/0001437749-26-022876-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/72444/000143774926022876/vxrt20260706_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-07T12:05:15.548163+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}